Get the Stockscreener App
0.3991
1.51%
-0.0061
After Hours:
.41
0.0109
+2.73%
Reviva Pharmaceuticals Holdings Inc stock is traded at $0.3991, with a volume of 1.52M.
It is down -1.51% in the last 24 hours and down -40.79% over the past month.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
See More
Previous Close:
$0.4052
Open:
$0.42
24h Volume:
1.52M
Relative Volume:
0.98
Market Cap:
$19.16M
Revenue:
-
Net Income/Loss:
$-37.65M
P/E Ratio:
-0.239
EPS:
-1.67
Net Cash Flow:
$-24.14M
1W Performance:
+2.02%
1M Performance:
-40.79%
6M Performance:
-77.45%
1Y Performance:
-63.05%
1-Day Range:
$0.3922
$0.42
1-Week Range:
$0.38
$0.4488
52-Week Range:
$0.30
$4.28
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Name
Reviva Pharmaceuticals Holdings Inc
Sector
Industry
Phone
(408) 501-8881
Address
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.3991 | 26.60M | 0 | -37.65M | -24.14M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-20-23 | Initiated | ROTH MKM | Buy |
| Jun-08-23 | Initiated | The Benchmark Company | Speculative Buy |
| Jan-24-22 | Initiated | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News
Is Reviva Pharmaceuticals Holdings Inc. a good long term investmentFree Consultation - Jammu Links News
What drives Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock priceFree Stock Market Return Analysis - Jammu Links News
What drives Reviva Pharmaceuticals Holdings Inc. stock priceUnmatched profit potential - Jammu Links News
What analysts say about Reviva Pharmaceuticals Holdings Inc. Equity Warrant stockRecord-breaking capital gains - Jammu Links News
Reviva Pharmaceuticals Holdings Inc. Equity Warrant Stock Analysis and ForecastLightning-fast capital gains - Jammu Links News
How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock performs during market volatilityWealth Building Stock Portfolio - Newser
Reviva Pharmaceuticals Holdings Inc. Stock Analysis and ForecastStrongest growth potential - Jammu Links News
Is Reviva Pharmaceuticals Holdings Inc. Equity Warrant a good long term investmentRapid capital growth - Jammu Links News
Can Reviva Pharmaceuticals Holdings Inc. stock recover from recent declineDefensive Stock Picks with Upside - Newser
Why Reviva Pharmaceuticals Holdings Inc. stock attracts strong analyst attentionFree Consultation - Newser
What makes Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock price move sharplyFree Stock Market Entry & Exit Signals - Newser
What makes Reviva Pharmaceuticals Holdings Inc. stock price move sharplyCapital Doubling Tips - Newser
Reviva Pharmaceuticals Holdings Inc: Analyzing RVPH Stock Trends - investchronicle.com
Why Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser
How Reviva Pharmaceuticals Holdings Inc. stock performs during market volatilityReal Time Stock Signal - Newser
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals’ (RVPH) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Reviva Pharmaceuticals Makes A $10 Million Stock Offering Move - Finimize
Reviva Pharmaceuticals (RVPH) Launches $10M Public Offering - GuruFocus
Dow Surges 200 Points; US GDP Contracts 0.5% - Benzinga
Reviva Pharmaceuticals (RVPH) Announces Public Offering of Commo - GuruFocus
Reviva Pharmaceuticals (RVPH) Declines After Announcing Public Offering - GuruFocus
Reviva Pharmaceuticals stock falls after announcing public offering By Investing.com - Investing.com Canada
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Buy” by Brokerages - Defense World
Ameriprise Financial Inc. Takes $84,000 Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
RVPH: Open Label Extension Results & Key Opinion Leader Discussion - MSN
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Pharma Reveals New Pipeline Updates at Major Neuroscience Conference - Stock Titan
Data Readout Positive from Trial of New Schizophrenia Drug - streetwisereports.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals (RVPH) Receives Buy Rating from D. Boral - GuruFocus
Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - MarketScreener
Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq
Reviva reports positive year-long schizophrenia drug study - Investing.com Australia
Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia - TipRanks
Reviva Pharmaceuticals Reports Positive 1-Year Phase 3 Results for Brilaroxazine in Schizophrenia, Highlighting Efficacy and Safety - Nasdaq
Reviva Announces Positive Full Dataset for 1-Year Phase 3 - GlobeNewswire
Breakthrough in Schizophrenia Treatment: Phase 3 Trial Reveals Sustained Efficacy Over 12 Months - Stock Titan
Open Label Phase 3 Study of Brilaroxazine for Schizophrenia Shows Efficacy, Tolerability - Psychiatric Times
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Shares Sold by Millennium Management LLC - Defense World
Reviva Pharmaceuticals Launches $50M At-Market Offering - TipRanks
Reviva Pharmaceuticals Holdings IncEnters Into At Market Issuance Sales AgreementSEC Filing - marketscreener.com
Reviva Pharmaceuticals' $50M ATM Offering: Navigating Dilution to Seize Brilaroxazine's Regulatory Catalysts - AInvest
What is Zacks Small Cap’s Estimate for RVPH Q2 Earnings? - Defense World
Roth Capital Issues Positive Forecast for RVPH Earnings - Defense World
D. Boral Capital Lowers Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $3.00 - Defense World
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):